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Dysfunction in ALS
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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized 
by the degeneration of cortical and spinal cord motor neurons. Several mechanisms 
have been implicated in the pathogenesis of the disease, including mitochondrial 
dysfunction, oxidative stress, and genome instability. Recently, a combined role 
between impaired DNA repair and subsequent mitochondrial dysfunction has 
emerged as a novel pathological interaction in neurodegeneration. This is exempli-
fied by mutations in the RNA-/DNA-binding proteins FUS and TDP-43 as well as 
superoxide dismutase 1 (SOD1) gene, all related to familial ALS. In this regard, 
evidence supports either downregulation or impaired recruitment of DNA repair 
enzymes in both nuclear and mitochondrial genomes. In addition, evidence also 
suggests a complex metabolic dysregulation as a critical component in the promo-
tion of the disease. This chapter aims to integrate the molecular mechanisms of this 
pathological interplay and the possible role in cytosolic protein aggregation and cell 
death in motor neurons.
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1. Genome instability in the context of ALS pathogenesis
ALS has been traditionally classified as sporadic or familial (fALS). Specifically, 
four genes account for up to 70% of all cases of fALS: C9orf72, TARDBP (encod-
ing TDP-43), SOD1, and FUS. Despite the Mendelian inheritance pattern, familial 
forms of ALS are usually characterized by incomplete penetrance, whereas genetic 
pleiotropy or oligogenic inheritance is suggested in individuals with sporadic 
disease [1]. Several hallmarks of neurodegeneration are shared in both familial and 
sporadic ALS, such as protein aggregation, defective autophagy, impaired DNA 
damage response (DDR), and mitochondrial dysfunction [1–3]. As ALS is a com-
plex disease, it is plausible to think that regardless of the etiology, there is an inter-
play between these hallmarks in the pathogenesis and pathological progression.
Considering the late age of onset and the neurological tropism, which is the 
exclusive neurological affectation, it is possible to highlight some aspects of 
the nervous system that are useful to understand the molecular pathology of the 
disease. First, due to its high rate of oxygen consumption and metabolic activity, 
the nervous system is more susceptible to DNA damage [4]. Single-strand breaks 
(SSBs) are considered the most common damage to DNA in cells [5], mainly derived 
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from reactive oxygen species [6]. Even physiological brain activity can also cause 
DNA double-strand breaks (DSBs) in neurons [7]. However, as neurons do not 
divide, homologous recombination (HR) is not available for DNA repair. In addi-
tion, to maintain normal functioning, neurons must ensure to keep mitochondrial 
homeostasis. Thus, there are different areas with high demands for ATP like synaptic 
terminals, active growth cones, or axonal branches that contain more mitochondria 
than other cellular domains [8, 9]. This dependency on mitochondrial homeostasis 
makes neurons more susceptible and more likely to be affected by mutations in 
genes regulating mitochondrial dynamics. For example, mutations in MFN2 and 
GDAP1 (which regulate mitochondrial fusion and fission, respectively) are related 
to Charcot-Marie-Tooth [10, 11], a peripheral neuropathy that resembles some of 
the clinical manifestations of ALS, especially in motor neurons. Thus, a disruption 
in normal nuclear and mitochondrial DNA (mtDNA) repair would affect motor 
neurons in a progressive way. Supporting this idea, several works have reported 
mtDNA mutations in presymptomatic animal models of ALS [12]. In fact, similar 
to CMT, mitochondrial axonal transportation has also been implicated in ALS. The 
SOD1-G93A mice showed alterations in the axonal traffic of mitochondria at a 
presymptomatic stage, specifically in motor neurons [13].
Interestingly, recent studies demonstrated that loss-of-function mutations in 
KIF5A are also a cause of ALS [14, 15]. KIF5A gene encodes for a specific motor pro-
tein implicated in the axonal transport of mitochondria. Although it was previously 
related with CMT and spastic paraplegia [16, 17], the new variants associated with 
ALS are primarily located at the C-terminal cargo-binding tail domain. Notably, 
patients harboring loss-of-function mutations displayed an extended survival rela-
tive to typical ALS cases.
A second aspect behind neurons’ susceptibilities is their high rate of transcrip-
tion. As they depend on the available DNA repair machinery, genomic stability is 
crucial for the maintenance of homeostasis. Transcription-driven DNA damage 
can arise from several sources, like the collapse of transcription machinery and 
subsequent DSBs, damage to genomic segments that have been opened up for 
transcription, and the formation of unnatural R-loop structures [18–21]. In the case 
of ALS cells, deficient DNA repair was reported more than three decades ago [22]. 
It seems that the DDR system in ALS loses adaptive capacity in dependency on the 
underlying genetic mutation [23]. The next chapter will address the role of the main 
genes involved in fALS in the generation of genomic instability as a hallmark of 
neurodegeneration.
2. Role of ALS-related genes in DDR
The hexanucleotide GGGGCC repeat expansion in C9ORF72 is one of the most 
common genetic causes of both ALS and frontotemporal dementia (FTD). It was 
recently demonstrated that these expansions could cause defective DNA repair, 
manifested by higher levels of DSBs and impaired DDR [24]. Defective ATM-
mediated DNA repair was found as a consequence of p62 accumulation, which 
impairs H2A ubiquitylation and perturbs ATM signaling. Another study reported 
that c-H2AX, p-ATM, 53BP1, and PARP1 were upregulated in C9orf72 patient 
spinal cords [25]. However, the mechanism behind the damage to the genome was 
not addressed. Authors suggest that R-loops, as well as the expression of dipeptide 
repeat proteins, are more likely to be the cause. Consistent with this notion, ele-
vated levels of DNA damage markers γH2AX, ATR, GADD45, and p53 were present 
in motor neurons differentiated from iPSC lines from C9orf72-mutant ALS patients 
in response to oxidative stress [26].
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In a model of C9orf72-induced ALS, the overexpression of SETX or depletion of 
p62 was capable of reducing γH2AX foci in MRC5 cells. In fact, the combined over-
expression of SETX and depletion of p62 further reduced DSB levels compared to 
levels observed by SETX overexpression or p62 depletion alone [24]. Interestingly, 
mutations in SETX cause both ataxia with oculomotor apraxia type 2 (AOA2) (auto-
somal recessive) and amyotrophic lateral sclerosis 4 (ALS4) (autosomal dominant). 
The N-terminal protein interaction and C-terminal RNA/DNA helicase domains are 
conserved in the Saccharomyces cerevisiae SETX homolog Sen1p. In a mutant model 
of Sen1p in S. cerevisiae, alterations in redox state, unfolded protein response, TOR, 
and severe loss of mitochondrial DNA were demonstrated [27].
Other ALS-related genes can cause DNA damage. The cytoplasmic inclusions of 
TDP-43 and FUS seen in ALS can be derived from a toxic gain of function, which, 
in turn, triggers motor neuron cell death [18]. As the majority of ALS-causing 
mutations are located within the C-terminus of FUS, it has been suggested that 
these mutations impair the DNA pairing function of FUS, compromising genome 
stability [28]. Moreover, depletion of either FUS or TDP-43 in cells treated with 
α-amanitin (an RNA Pol II inhibitor) led to higher DNA strand breaks [18]. It also 
was demonstrated that after UV damage-induced transcription arrest, FUS local-
izes at genomic sites where active transcription has been arrested by DNA damage, 
and it does so together with BRCA1 [18]. TDP-43 is also able to localize at sites of 
transcription-associated DNA damage, given its colocalization with γH2AX and 
phosphorylated RPA. Interestingly, TDP-43 also colocalized with γH2AX and 
phosphorylated RPA in undamaged cells, consistent with its role in preventing or 
repairing spontaneously arising DNA damage [18].
FUS and TDP-43 are also required to maintain R-loop homeostasis since their 
depletion leads to R-loop-mediated genomic instability [29]. It is speculated that 
RNA processing factors prevent R-loop by binding to the nascent RNA transcript 
and blocking R-loop formation. In this regard, it has been shown that FUS and 
TDP-43 colocalize with active RNA polymerase II at sites of DNA damage along 
with BRCA1, either to prevent or repair R-loop-associated DNA damage, normally 
considered an indicator of defective transcription and/or RNA processing [18].
3. Mitochondrial dysfunction in ALS
The space-time location of mitochondria is vital for the metabolic requirements 
of the nervous system, especially in the case of motor neurons. As neurons can-
not rely on glycolysis, mitochondria are crucial to meet the high energy demands 
mainly by oxidative phosphorylation (OXPHOS). Several aspects of mitochondrial 
dynamics have been involved in the pathogenesis of ALS. For example, ATP genera-
tion was markedly decreased in neuronal cells of mutant SOD1-G93A mice [30, 31]. 
Moreover, cytosolic ATP levels were significantly reduced in neuroblastoma cells 
expressing mutant SOD1-G37R and in rotenone-treated SOD1-G93A neuronal cells 
[32]. Impairment of intracellular Ca2+ homeostasis is also considered as a hallmark 
of mitochondrial dysfunction in neurodegeneration. In this regard, an imbalance in 
Ca2+ dynamics has been reported in cells expressing both mutant SOD1-G93A and 
SOD1-G37R [33, 34] and in motor neurons from mutant SOD1-G93A transgenic 
mice [35].
Mitochondrial fusion and fission are also key processes to preserve organelle 
functioning and cellular homeostasis. Dynamin-related protein 1 (Drp1) influ-
ences cell survival and apoptosis by mediating the mitochondrial fission process in 
mammals [36]. An excessive mitochondrial fragmentation and dysfunction were 
reported in patient-derived fibroblasts and cultured motor neurons of several 
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familial forms of ALS expressing SOD1 mutant [37]. In the same article, authors 
demonstrated that inhibition of Drp1/Fis1 interaction led to a significant reduction 
in ROS levels and improved mitochondrial function and structure. Mutations in 
SOD1, TARDBP, or FUS are related to protein aggregation. In this regard, aggre-
gated proteins can also contribute to mitochondrial dysfunction. Moreover, ATP 
decrease and ROS increase are the main features of mitochondrial damage. While 
ROS can increase Drp1 leading to sustained mitochondrial fission and fragmenta-
tion, a decrease in ATP levels can impair autophagy and proteasomal degradation. 
This can worsen protein aggregates and trigger ER stress [37, 38].
More than two decades ago, Kong and Xu reported that in mice expressing 
SOD1-G93A, the onset of the disease involved a decline of muscle strength and a 
transient explosive increase in vacuoles derived from degenerating mitochondria. 
Interestingly, this damage did not involve motor neuron death at the time of onset. 
Based on their results, the authors suggested that SOD1-mutant toxicity was 
mediated by damage to mitochondria in motor neurons [39]. The early findings 
of mitochondrial dysfunction were also confirmed by Magrané and colleagues, 
who studied the mitochondrial transport within the sciatic nerve in SOD1-G93A 
and TDP-43-A315T mice. Defects of retrograde mitochondrial transport were 
detected at 45 days of age in both mice, before the onset of symptoms [40]. In the 
SOD1-G93A mice, mitochondrial morphological abnormalities were apparent at day 
15 of age, thus preceding transport abnormalities. Conversely, in TDP-43-A315T 
mice, morphological abnormalities appeared after the onset of transport defects. 
Interestingly, the authors reported neither morphological nor mitochondrial distri-
bution changes in sensory neurons [40].
Another study evaluated the role of SOD1 mutations in mitochondrial homeo-
stasis, in spinal cord sections from early symptomatic 10-month mice. Authors 
showed that mutant SOD1 binding to mitochondria disrupts normal distribution 
and morphology as an early pathogenic feature. In their work, mitochondria from 
SOD G85R/G37R mice became progressively smaller and rounder and are unevenly 
distributed along axons [41]. As in SOD1 mutant experiments, oxidative stress 
and DNA damage were increased in iPSC-derived C9ORF72 motor neurons in 
an age-dependent manner [26]. Poly (GR) preferentially binds to mitochondrial 
ribosomal proteins and compromised mitochondrial function, which could lead to 
increased oxidative stress. Reducing oxidative stress partially rescued DNA damage 
in C9ORF72 motor neurons cells [26].
The role of mutant FUS and TDP-43 has also been evaluated in mitochondrial 
dysfunction. In cultured neurons expressing FUS-R495X, it was revealed that 
mutant FUS controlled the translation of genes that were associated with mitochon-
dria function, which resulted in a significant reduction of mitochondrial size [42]. 
Specifically, protein levels of KIF5B, DNM1L, and CSDE1 were significantly reduced 
in R495X-expressing neurons. FUS is also able to translocate and accumulate inside 
mitochondria. Following this approach, it was revealed that FUS could interact with 
mitochondrial chaperonin HSP60 and this interaction mediates FUS localization to 
the organelle, leading to damage [43]. This damage derives from reduced mitochon-
drial membrane potential and increased production of ROS. Authors also reported 
elevated HSP60 expression in two of three cases of FTLD-FUS patients’ brain 
samples. Curiously, mutations in the HSPD1 gene which encodes for HSP60 protein 
have also been found in patients with spastic paraplegia type 13 [44]. Another work 
revealed that mitochondrial impairment is a critical early event in FUS proteinopa-
thy. When mutant FUS-P525L accumulated inside mitochondria, it interacted with 
the mitochondrial ATP synthase catalytic subunit ATP5B and reduced mitochondrial 
ATP synthesis. Importantly, FUS accumulation also induced the mitochondrial 
unfolded protein response (UPTmt), making the damage even worse [45].
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Similarly, mutant TDP-43 accumulates in the mitochondria of neurons in 
subjects with ALS or frontotemporal dementia (FTD). Wild-type and mutant TDP-
43 preferentially bind to mitochondria-transcribed mRNAs encoding respiratory 
complex I subunits ND3/ND6, causing complex I disassembly [46]. The suppres-
sion of TDP-43 mitochondrial localization abolished mitochondrial dysfunction 
and neuronal loss and improved the phenotypes of transgenic mutant TDP-43 mice. 
Mutant FUS can also alter mitochondrial-endoplasmic reticulum (ER) communica-
tion. Stoica and colleagues showed that FUS disrupts the VAPB-PTPIP51 complex, 
impairing ER-mitochondria association. As a consequence, there was a perturbation 
of Ca2+ uptake by mitochondria and impaired ATP production [47]. Remarkably, 
inhibition of glycogen synthase kinase-3b (GSK-3b) corrected FUS-induced defects 
in ER-mitochondria associations and mitochondrial Ca2+ levels.
Mitochondrial DNA damage is also important in the context of neurodegen-
erative diseases [48, 49]. Maintaining mitochondrial DNA stability is critical for 
cellular function, especially in the context of the nervous system. Several pathways 
have been implicated in mtDNA repair, but base excision repair (BER) is the 
predominant one [50]. Oxoguanine glycosylase 1 (OGG1) is an enzyme that plays a 
major role in the mitochondrial BER pathway, removing 8-hydroxy-2-deoxyguano-
sine (8-OHdG). In the spinal cord of SOD1 mutant transgenic mice, the presence of 
8-OHdG was progressively accumulated in the ventral horn neurons from early and 
presymptomatic stage (25 weeks) [51]. This was a suggestion that an oxidative dam-
age to mitochondrial DNA was affecting spinal motor neurons at a very early stage 
of the disease. Early and selective impairment of DNA repair enzymes in mitochon-
dria was also reported in presymptomatic transgenic mice carrying a mutant SOD1 
gene [51]. Notably, the selective expression of these enzymes in spinal neurons is 
closely related to the selective involvement of motor neurons in ALS.
In the ALS but not control brains, levels of a common mitochondrial DNA dele-
tion mutation (mt DNA4977) were an average of more than 30-fold in Brodmann 
area 4 [52]. In addition, the oxidative damage derived from 8-oxoG was accumu-
lated in the mitochondria of motor neurons in ALS, and according to previous 
findings, OGG1 did not repair the damage efficiently, driving the loss of motor 
neurons in ALS [53]. Likewise, motor neurons in G93A-mSOD1 transgenic mice 
undergo slow degeneration characterized by mitochondrial swelling and forma-
tion of DNA single-strand breaks prior to double-strand breaks occurring in both 
nuclear and mitochondrial DNA [54]. These cells accumulated mitochondria from 
the axon terminals and generated higher levels of ROS/RNS. Despite experimental 
evidence demonstrating mtDNA damage, more research is required to elucidate the 
mechanisms that lead to mitochondrial damage in ALS. The mechanisms that can 
link the DNA repair deficiency induced by errors in ALS-associated proteins and 
the subsequent mitochondrial dysfunction in terms of genetic integrity are not yet 
understood. We believe that this is an issue that should be taken into account for 
future studies.
4. Nuclear-mitochondrial interplay and genomic integrity in ALS
4.1 The role of SIRT1-PARP1 axis
Poly (ADP-ribose) polymerase 1 (PARP1) is a NAD+-dependent protein. It is 
able to posttranslationally modify itself and other proteins involved in multiple 
DDR. PARP1 is also crucial for the stabilization of DNA replication forks and chro-
matin remodeling [55]. Deletion of Parp1 gene in Xrcc1 knockout mice is able to pre-
vent neurodegeneration, indicating that the overactivation of PARP1 is a neurotoxic 
Amyotrophic Lateral Sclerosis - Recent Advances and Therapeutic Challenges
6
consequence of defective DNA repair [56]. Recently, it was demonstrated that 
FUS can bind directly to PAR, the polymer made by PARP1 [57]. Authors revealed 
that FUS is recruited to chromosomal sites of oxidative DNA damage and that this 
recruitment is reduced by the FUS-R521G mutation. Additionally, when cells lack 
PARP1, FUS failed to accumulate at sites of UVA laser-induced damage. Moreover, 
under oxidative stress, PARP1 activity increases, leading to an accumulation of 
ADP-ribose polymers and NAD+ depletion. This condition induces a metabolic 
and energetic crisis driving cell death [58]. As PARP1 hyperactivation and toxicity 
have been implicated in diseases like Alzheimer’s, Parkinson’s, and Huntington’s, a 
predominant role in ALS is also plausible [59].
Sirtuins are also NAD-dependent proteins. SIRT1 is known as a nuclear and 
cytoplasmic deacetylase, which is predominantly expressed in neurons in the con-
text of the nervous system [60]. Notably, PARP1 consumes NAD+, reducing SIRT1 
activity by increasing PARylation of DNA and proteins involved in DDR. Thus, 
SIRT1 activity appears to be impeded by PARP1 hyperactivation [61]. Interestingly, 
NAD+ replenishment shows a reactivation of SIRT1 and prevented neurodegenera-
tion [62]. Thus, compromised DNA repair leads to PARP1 hyperactivation, result-
ing in the depletion of NAD+ levels, inhibiting SIRTs (Figure 1). Notably, the Km 
of SIRT1 for NAD+ is higher than that of PARP1, so when NAD+ levels become so 
low following cell stress or senescence, SIRT1 no longer has the chance to regulate 
the activity of PARP1 [61]. Cantó and colleagues demonstrated that deletion of 
Parp1 gene increased NAD+ levels and SIRT1 activity in brown adipose tissue and 
muscle. Parp1 −/− mice presented a higher mitochondrial content, resulting in 
increased energy expenditure and protection against metabolic disease. As previ-
ously reported, authors showed that pharmacologic inhibition of PARP in vitro 
and in vivo increased NAD+, leading to SIRT1 expression and enhanced oxidative 
metabolism [63].
SIRT1 is vital in the maintenance of metabolic homeostasis [64]. SIRT1 can 
activate the peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α 
(PGC-1α) through deacetylation [65]. PGC-1a can regulate genes of the ROS 
defense system. It has been shown that PGC-1a can protect WT neural cells from 
oxidative stress by increasing the expression of ROS-detoxifying genes includ-
ing SOD1/SOD2 and UCP2 [66]. SIRT1 may also deacetylate PGC-1α to induce 
mitochondrial biogenesis by increasing mitochondrial gene expression via nuclear 
respiratory factor 1 (NRF-1) and nuclear-encoded mitochondrial transcription 
factor A (TFAM) [67]. Interestingly, it was revealed that PGC-1 and SIRT1 are 
also present inside the mitochondria and are in close proximity to mtDNA [68]. In 
addition, an unexpected role for serotonin (5-HT) was also recently demonstrated. 
Fanibunda and colleagues showed that in rodent cortical neurons, serotonin is a 
regulator of mitochondrial biogenesis, via 5-HT2A receptor-mediated recruitment 
of the SIRT1-PGC-1α axis [69].
SIRT1 can form a protein complex with the Forkhead transcription factor 
FOXO3 and promote its deacetylation. SIRT1 induces several effects mediated by 
FOXO3 like cell cycle arrest and transcription of DNA repair target genes [70]. 
Cantó and colleagues demonstrated that AMPK enhances SIRT1 activity by increas-
ing cellular NAD+ levels [71]. This resulted in the deacetylation and modulation of 
the activity of downstream SIRT1 targets including PGC-11α and FOXO1/FOXO3a 
transcription factors. Thus, SIRT1 could promote both mitochondrial biogenesis 
in conditions of energy deficiency in disease or induce the clearance of damaged 
mitochondria [72].
In XPA-deficient cells, a model of xeroderma pigmentosum, the DNA repair 
deficiency leads to PARP1 activation, and the attenuated NAD+/SIRT1/PGC-1α 
axis resulted in defective mitophagy. The condition could be rescued either by 
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PARP1 inhibition or by supplementation with NAD+ [73]. In a different work, 
Scheibye-Knudsen and colleagues showed that hyperactivation of PARP1 drives 
SIRT1 depression in Cockayne syndrome (CS). Similar to previous findings, NAD+ 
replenishment rescued the phenotype in CS, but in this case, they also demon-
strated that diet can also increase SIRT1 activity [62]. Following the same line, it 
was revealed that NAD+ levels are reduced in aged mice and Caenorhabditis elegans 
[74]. Genetic or pharmacological restoration of NAD+ prevented age-associated 
metabolic decline and promoted longevity in worms. These effects were associated 
with deacetylase sir-2.1 levels, the homolog of SIRT1. Indeed, hyperacetylation of 
the SIRT1 substrate PGC-1α resulted from low levels of NAD+ in aged mice [74]. 
Supporting this approach, it was demonstrated that the intracellular nicotinamide 
phosphoribosyltransferase (iNAMPT) is essential to projection neuron function 
and viability. The iNAMPT is the rate-limiting enzyme of the mammalian NAD+ 
biosynthesis. When eliminating Nampt in adult mice, the resulting phenotype 
Figure 1. 
Nuclear-mitochondrial interplay in the context of ALS. (A) Activation of PARP1 upon DNA damage 
facilitates DNA repair but inhibits SIRT1 due to NAD+ depletion. FUS binds directly to PAR, the polymer 
made by PARP1 in chromosomal sites of oxidative DNA damage. Both TDP-43 and FUS localize at genomic 
sites where active transcription has been arrested by DNA damage and also maintain R-loop homeostasis. 
SETX is also necessary for R-loop repair. In addition, FUS interacts with HDAC1 and enhances its activity 
in both physiological conditions and DNA damage. (B) SIRT1 positively regulates DDR. SIRT is able to 
deacetylase HDAC1, ATM, WRN, TDG, XPA, and KU70. (C) SIRT1 also regulates mitochondrial homeostasis 
through AMPK, FOXOs, and PGC1α. These enzymes regulate mitochondrial biogenesis and oxidative 
stress, transcribing proteins such as UCP2 and SODs. (D) Accumulation of misfolded proteins leads to the 
aberrant p62 expression, disrupting normal mitophagy. Likewise, defective ATM-mediated DNA repair is a 
consequence of p62 accumulation and RNF168 inhibition. C9orf72 can also cause defective DNA repair and 
p62 accumulation with the subsequent impaired mitophagy. (E) ALS-related mitochondrial dysfunction leads 
to mitochondrial fragmentation through DRP1 overexpression, decreased ATP production, higher ROS levels, 
mtDNA damage, decrease in OXPHOS, and Ca+2 imbalance. FUS can accumulate inside the mitochondria, 
leading to impaired ATP production and increased ROS levels. C9ORF72 can also generate oxidative stress 
and mtDNA damage in motor neurons. TDP-43 preferentially bind to mitochondria-transcribed mRNAs, 
causing complex I disassembly. SOD1 mutations can decrease cytosolic ATP levels, impair intracellular Ca2+ 
homeostasis, generate excessive mitochondrial fragmentation, and deregulate DDR. The final effect of this 
cascade is derived from mitochondria-ER stress, consequent misfolded proteins, and further protein aggregation. 
Dotted lines illustrate pathological interactions.
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resembled ALS: motor neuron degeneration, hypothermia, motor dysfunction and 
paralysis, reduced general motor activity, and anxiety-like behaviors. Remarkably, 
nicotinamide mononucleotide (NMN), a NAD+ precursor, improved health span, 
restored motor function, and extended lifespan [75]. Since the authors also found 
that iNAMPT protein levels were significantly reduced in the spinal cord of ALS 
patients, the NAD+/SIRT1 axis represents an outstanding therapeutic opportunity.
For a long time, the beneficial effect of resveratrol has been controversial due 
to inconsistent results and tissue-dependent effects. Price and colleagues showed 
that a moderate dose of resveratrol is able to stimulate the AMPK activity, increase 
NAD+ levels, enhance mitochondrial biogenesis, and improve mitochondrial 
function. All of these functions were entirely dependent upon SIRT1 in skeletal 
muscle [76]. Interestingly, a tenfold higher dose of resveratrol activated AMPK in 
a SIRT1-independent manner, although improvements in mitochondrial function 
were SIRT1 dependent [76]. Finally, it was demonstrated that resveratrol-mediated 
SIRT1 activation protects against p25 and mutant SOD1-G93A neurotoxicity both 
in vitro and in vivo [77].
4.2 The role of SIRT in DDR
Beyond its role in metabolism, SIRT1 is also important in DNA repair. In post-
mitotic neurons, SIRT1 was rapidly recruited to DSBs where it showed a synergistic 
relationship with ATM, stimulating its autophosphorylation and stabilizing ATM at 
DSBs’ sites [78]. Additionally, authors reported that after DSBs’ induction, SIRT1 
also bound HDAC1, a neuroprotective histone deacetylase, stimulating its enzy-
matic activity. This activity is necessary for the nonhomologous end joining (NHEJ) 
pathway [78]. Likewise, upon exposure to radiation, SIRT1 can enhance DNA repair 
capacity and deacetylation of repair protein Ku70, involved in NHEJ as well [79].
SIRT1 also interacts with WRN both in vitro and in vivo, and this interaction 
is enhanced after DNA damage [80]. WRN is a member of the RecQ DNA helicase 
family with functions in maintaining genome stability. Moreover, the MRE11-
RAD50-NBS1 (MRN) is a conserved nuclease complex that exhibits properties of 
a DNA damage sensor in the context of DSBs. SIRT1 can associate with the MRN 
complex and maintains NBS1 in a hypoacetylated state following ionizing radiation 
[81]. SIRT1 is also important for the base excision repair (BER) pathway. It was 
shown that SIRT1 deacetylates APE1 in vitro and in vivo following genotoxic insults 
[82]. Knockdown of SIRT1 increases cellular abasic DNA content, sensitizing cells 
to death induced by genotoxic stress. Interestingly, the activation of SIRT1 with 
resveratrol promoted binding of APE1 to XRCC1 [82]. Thymine DNA glycosylase 
(TDG) is an essential multifunctional enzyme also involved in BER. SIRT1 was 
shown to interact with TDG and enhance its glycosylase activity due to deacety-
lation [83]. Nucleotide excision repair (NER) is another important pathway in DNA 
repair. NER removes DNA damage induced by ultraviolet light (UV). Xeroderma 
pigmentosum group A (XPA) is a critical protein for this process. SIRT1 interacts 
with XPA, and the interaction is enhanced after UV irradiation [84]. In fact, down-
regulation of SIRT1 sensitized cells to UV irradiation.
4.3 The role of FUS in DDR
FUS is important for both NHEJ- and HR-mediated DSB repair in neurons. As 
SIRT1, FUS interacts with HDAC1 and enhances its activity in both physiological 
conditions and DNA damage in cortical neurons [85]. The same was demonstrated 
in human-induced pluripotent stem cells (hiPSCs) and hiPSC-derived motor 
neurons. The degree of FUS mislocalization correlated well with the clinical severity 
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of the underlying ALS, with a higher accumulation of DNA damage in postmitotic 
mutated FUS motor neurons than in dividing hiPSCs [86]. Although FUS has been 
associated with multiple DNA repair pathways including DSB repair, quantifica-
tion of the level of DNA SSBs vs. DSBs in FUS knockdown (KD) and knockout 
(KO) cells by comet analysis revealed that most unrepaired DNA strand breaks that 
accumulated after the loss of FUS were SSBs [87].
FUS protects the genome by facilitating PARP1-dependent recruitment of 
XRCC1/DNA ligase IIIα (LigIII) to oxidized genome sites and activating LigIII via 
direct interaction [88]. Cells presenting mutant FUS showed a significantly reduced 
association between this DNA repair protein complex, SSBs’ accumulation, and 
ROS levels in motor neurons. LigIII was demonstrated to be an essential enzyme for 
mtDNA integrity but dispensable for nuclear DNA repair [89]. LigI was critical for 
nuclear DNA repair in a cooperative manner with LigIII, but inactivation of LigIII 
resulted in mtDNA loss, mitochondrial dysfunction, and incapacitating ataxia in 
the mouse nervous system. However, as neurons do not divide, it is possible that 
LigIII is equally important for nuclear DNA repair. Following the idea that mtDNA 
integrity is vital in postmitotic tissues, the authors also found that inactivation of 
LigIII in cardiac muscle resulted in mitochondrial dysfunction and defective heart-
pump function leading to heart failure [89]. More research is needed to elucidate 
the interaction of ALS-associated proteins with both nuclear and mitochondrial 
DNA repair enzymes (Figure 1).
4.4 Cross talk between auto-/mitophagy and DNA repair in ALS
Autophagy is a crucial process to eliminate misfolded proteins and organelles. 
Mitophagy is a special subroutine of autophagy, involved in the maintenance of 
mitochondrial homeostasis. An important protein regulating this process is p62. 
The molecular mechanism of p62-mediated mitochondrial defective clearance 
was demonstrated by Geisler and colleagues [90]. Knockdown of p62 significantly 
diminished mitochondria recognition by the autophagy machinery and its sub-
sequent elimination [91]. Notably, accumulation of misfolded proteins leads to 
the aberrant p62 expression, which influences the balance of mitophagy, worsens 
mitochondrial dysfunction, and induces more protein aggregates [92]. This can 
explain the vulnerability of non-cycling cells to proteinopathies in the context of 
mitochondrial dysfunction [93–96].
Autophagy is also important to maintain functional DNA repair by prevent-
ing p62 accumulation. In the context of ALS, where p62 accumulates, RNF168-
mediated H2A ubiquitylation (U) is perturbed, leading to impaired DSBs’ repair 
and genomic instability [29]. Wang and colleagues reported that p62/SQSTM1, 
which accumulates in autophagy-defective cells, directly binds to and inhibits 
nuclear RNF168, which is crucial for histone H2A ubiquitination and DNA damage 
responses. As a result, DNA repair proteins such as BRCA1, RAP80, and Rad51 can-
not be recruited to the sites of DNA double-strand breaks (DSBs), which impairs 
DSBs’ repair [97]. The interaction between mitochondrial dysfunction, defective 
mitophagy, and protein aggregation should be the subject of further investigation. 
This could generate new therapeutic avenues in the context of neurodegenerative 
diseases that occur with proteinopathies.
5. Therapeutic challenges and opportunities
Despite the clear role of mitochondria in neurodegeneration, the application 
of translational medicine in this field remains to be addressed. The lack of new 
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therapeutic options and the limitations of current genetic editing techniques make 
it difficult to have a clear path for future research. Due to the failure in targeting 
specific aspects of mitochondria, mitochondrial transplantation presents a new 
paradigm of therapeutic intervention that may benefit neuronal survival and 
regeneration in ALS and similar diseases. The clinical application of mitochondrial 
transplantation was extensively reviewed by Chang and colleagues already [98].
The importance of this approach has been demonstrated in different lines of 
research. For example, it was shown that astrocytes in mice release functional 
mitochondria that enter neurons and amplify cell survival signals after stroke [99]. 
Cardiomyocytes share several similitudes with neurons, including the postmitotic 
state, the high transcription rate, the similar metabolic profile, and the underlying 
dependence on mitochondrial homeostasis. Following myocardial ischemia and 
reperfusion (IR), several alterations have been demonstrated in mitochondrial 
structure and function. Mitochondrial transplantation has been proposed as a 
strong opportunity for the treatment of IR [100]. Masuzawa and colleagues showed 
in a model of ischemia-reperfusion injury that transplantation of autologously 
derived mitochondria immediately prior to reperfusion ameliorated the damage. 
By using New Zealand white rabbits, they demonstrated a complete recovery and 
showed that the transplanted mitochondria enhanced oxygen consumption, high-
energy phosphate synthesis, and enhanced post-infarct cardiac function [101].
In a model of Parkinson’s disease induced by the respiratory chain inhibitor 
MPTP, Shi and colleagues demonstrated in mice that intravenous injection of 
mitochondria prevented the progression of the disease. Specifically, the authors 
reported increased activity of the electron transport chain, decreased ROS levels, 
and prevention of cell apoptosis and necrosis [102]. Other approaches have been 
addressed following this so-called mitochondrial medicine approach in ALS, such 
as ketogenic diet, antioxidants, and metabolic targeting drugs [103]. Based on 
the evidence provided until this point, mitochondrial transplantation should be 
validated as a therapeutic option in ALS. The safety and efficacy, delivery strategies, 
the periodicity of the transplant, and the capture by the cells of interest should be 
rigorously analyzed experimentally. Thus, if its effectiveness is proven in animal 
models, hopefully, clinical trials can be performed soon.
6. Conclusions
The DNA repair deficiency is a hallmark that combines at the pathological level 
with mitochondrial dysfunction, which highlights the special dependence of neu-
rons on genomic integrity and metabolic stability. This highlights what we called the 
pathological tropism of the nervous system. At this point, it is clear that whatever 
the etiology behind ALS and motor neuron degeneration, mitochondrial dysfunc-
tion is present in all fALS and sporadic ALS patients. The fact that mitochondrial 
damage appears in the presymptomatic stage of the disease raises an opportunity 
for targeting mitochondria and hopefully makes disease progression slower or even 
stops it. Mitochondrial transplantation represents a promising avenue for the fol-
lowing years, as well as NAD+ repletion therapy and mitophagy-inducing agents.
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Nomenclature
ALS amyotrophic lateral sclerosis
fALS familial amyotrophic lateral sclerosis
DDR DNA damage response
DSBs double-strand breaks
NAD+ nicotinamide adenine dinucleotide
SETX senataxin
ROS reactive oxygen species
RNS reactive nitrogen species
NHEJ nonhomologous end joining
BER base excision repair
SIRT Sirtuin 1
FUS fused in sarcoma
HDAC1 histone deacetylase 1
HiPSCs human-induced pluripotent stem cells
PARP1 poly (ADP-ribose) polymerase 1
XRCC1 X-ray repair cross-complementing 1
TDP-43 TAR DNA-binding protein 43
SOD1 superoxide dismutase 1
C9orf72 chromosome 9 open reading frame 72
SSBs single-strand breaks
HR homologous recombination
MFN2 mitofusin 2
GDAP1 ganglioside-induced differentiation-associated protein 1
mtDNA mitochondrial DNA
KIF5A kinesin heavy chain isoform 5A
ATM ataxia telangiectasia mutated
53BP1 p53-binding protein 1
UPRmt mitochondrial unfolded protein response
FTD frontotemporal dementia
ER endoplasmic reticulum
GSK-3b glycogen synthase kinase-3b
PGC-1α peroxisome proliferator-activated receptor gamma coactivator-1 
alpha
iNAMPT intracellular nicotinamide phosphoribosyltransferase
NMN nicotinamide mononucleotide
RNF168 RING-type E3 ubiquitin transferase
BRCA1 breast cancer 1
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
AMPK MP-activated protein kinase
FOXOs forkhead box O proteins
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